Meet Our Team

Our leadership and advisory network brings expertise in emergency medicine, regulatory strategy, neuroscience, commercialization, and public health advocacy. Together, we support responsible scientific progress where critical gaps persist.

We are advancing Cerebro-1, a rapid lipid-sink intervention designed to address acute cannabinoid intoxication and CHS. Our team brings expertise across emergency medicine, regulatory strategy, neuroscience, commercialization, and patient advocacy to move this mission forward.

Executive

Jack Donaldson IV, M.Ed

Jack Donaldson IV, M.Ed

Founder and President

Click for more info

Click for more info

Candis Edwards

Candis Edwards

Chief Regulatory Officer

Click for more info

Click for more info

Flo Rida

Flo Rida

Strategic Partnerships Advisor

Click for more info

Click for more info

Advisory Board

Sir Winston Parris, MD

Sir Winston Parris, MD

Board Advisor, Pain Management & Addiction Medicine

Click for more info

Click for more info

Dr. George Tabi, MD

Dr. George Tabi, MD

Senior Scientific Advisor, Emergency Medicine and Cannabis

Click for more info

Click for more info

Dr. Steve Passick, MD

Dr. Steve Passick, MD

Senior Scientific Advisor, Strategy and Translational Research

Click for more info

Click for more info

Scientific Advisory Board

Dr. Kavan Clifford, MD, PhD

Dr. Kavan Clifford, MD, PhD

Senior Scientific Advisor, Pain and Neuroscience

Click for more info

Click for more info

James Tarver, PhD, MBA

James Tarver, PhD, MBA

Senior Scientific Advisor, Addiction and Educator

Click for more info

Click for more info

Dr. Kennon Heard, MD

Dr. Kennon Heard, MD

Senior Scientific Advisor, Emergency Medicine Toxicologis

Click for more info

Click for more info

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.